Prevalence, Strain Circulation and Disease Burden Study of Seasonal Influenza A and B in Panama, Selected Countries of Central America and the Caribbean From the Year 2010 to 2015
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02885246|
Recruitment Status : Completed
First Posted : August 31, 2016
Last Update Posted : September 27, 2018
|Condition or disease||Intervention/treatment|
|Influenza, Human||Other: Data collection|
The Gorgas Memorial Institute for Health Studies (ICGES) is a public health institution established in Panama dedicated to health research and disease prevention. It has been performing virological isolations of influenza and is a part of the World Health Organisation (WHO) Global Influenza Surveillance and Response System (GISRS) and a direct collaborator of the CDC.
From 2010 a sentinel surveillance program is being conducted in Panama within the ICGES to collect data on influenza and other respiratory viruses using CDC guidance for Respiratory Disease Surveillance. This study aims to utilize this data source for analyzing the burden of influenza within the region.
|Study Type :||Observational|
|Actual Enrollment :||1 participants|
|Official Title:||Prevalence, Strain Circulation and Disease Burden of Seasonal Influenza A and B in Panama, Selected Countries of Central America and the Caribbean From the Year 2010 to 2015|
|Actual Study Start Date :||September 11, 2017|
|Actual Primary Completion Date :||September 17, 2018|
|Actual Study Completion Date :||September 17, 2018|
All subjects who have laboratory confirmed diagnosis of influenza (laboratory confirmed case) and reported in the national influenza surveillance system from the Year 2010-2015.
Other: Data collection
The ICGES database of Panama will be checked for all seasonal influenza A and/or B positive cases reported via influenza surveillance programs from 2010 to 2015.
- Occurrence of seasonal influenza A and/or B cases by age, virus subtype and strain lineage, in Panama, selected countries of Central America and the Caribbean (using the data reported via National Influenza Surveillance Program). [ Time Frame: From January 2010 to December 2015 ]Assessment by age ranges- <1, 1-4, 5-9, 10-14, 15-19, 20-24, 25-44, 45-49, 50-59, 60-64 and ≥65 years, virus subtype- A-virus subtype (AH1N1/A H3N2) and B-strain lineage (Victoria and Yamagata).
- Occurrence of clinical features and outcomes (clinical symptoms, duration of illness, complications) experienced by subjects who have laboratory confirmed diagnosis seasonal influenza A and/or B. [ Time Frame: From January 2010 to December 2015 ]Clinical features and outcomes experienced by influenza positive subjects by type of influenza (seasonal influenza A and/or B) in different seasons from 2010-2015.
- Evaluation of frequency of seasonal influenza A and/or B cases reported in different temporal and geographical locations. [ Time Frame: From January 2010 to December 2015 ]Assessment by geographical distribution by country and by region within the country (if data available).
- Occurrence of influenza caused by B-strain and presented by B lineages among the study population by age and by region. [ Time Frame: From January 2010 to December 2015 ]Assessment by age ranges- <1, 1-4, 5-9, 10-14, 15-19, 20-24, 25-44, 45-49, 50-59, 60-64 and ≥65 and by selected study regions.
- Comparison of characteristics of the influenza B-infection as observed in the database and the B-strain included in the trivalent influenza vaccine. [ Time Frame: From January 2010 to December 2015 ]Estimation of the proportion of matched B-strains and mis-matched B-strains.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02885246
|GSK Investigational Site|
|Study Director:||GSK Clinical Trials||GlaxoSmithKline|